# A Randomised Open-label Phase III Trial of REduced Frequency Pembrolizumab immuNothErapy for First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

> **NCT05085028** · PHASE3 · RECRUITING · sponsor: **Imperial College London** · enrollment: 1750 (estimated)

## Conditions studied

- Lung Cancer, Nonsmall Cell

## Interventions

- **DRUG:** Pembrolizumab 25 MG/ML [Keytruda]

## Key facts

- **NCT ID:** NCT05085028
- **Lead sponsor:** Imperial College London
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-06-23
- **Primary completion:** 2027-05-31
- **Final completion:** 2027-05-31
- **Target enrollment:** 1750 (ESTIMATED)
- **Last updated:** 2024-03-07

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05085028

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05085028, "A Randomised Open-label Phase III Trial of REduced Frequency Pembrolizumab immuNothErapy for First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05085028. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*